Ireland's Jazz Pharma to buy GW Pharma in $7.2B deal
February 4, 2021
Jazz Pharmaceuticals has agreed to acquire Nasdaq-listed GW Pharmaceuticals for $7.2 billion in a cash-and-stock deal. Founded in 1998, UK-based GW specializes in cannabis-derived therapeutics. The deal gives Dublin-based Jazz access to seizure drug Epidiolex, the first prescription cannabidiol medicine to be approved by the FDA. Jazz will pay $220 per American depositary share, comprising $200 in cash and $20 in Jazz ordinary shares.